First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
Author:
Affiliation:
1. Shanghai Lung Cancer Center Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China
2. Department of Oncology Johns Hopkins Medical Institutions Baltimore MD USA
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Cancer Research,Radiology Nuclear Medicine and imaging,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2972
Reference25 articles.
1. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
2. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
3. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
4. Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
5. Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-World Outcomes of Crizotinib in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer;Cancers;2024-01-26
2. Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan;Future Oncology;2023-12
3. ROS1-Rearranged Lung Adenocarcinoma: From Molecular Genetics to Target Therapy;Onco;2023-08-22
4. Therapeutical Options in ROS1—Rearranged Advanced Non Small Cell Lung Cancer;International Journal of Molecular Sciences;2023-07-15
5. Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands;Lung Cancer;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3